

1                   **Optimization of the Cultural parameters for**  
2                   **Improved Production of Antimicrobial**  
3                   **Metabolites by *Streptomyces gulbargensis* DAS**  
4                   **131**

5  
6  
7  
8  
9  
10  
11 **ABSTRACT**  
12

---

**Aims:** To investigate the influence of appropriate culture medium by optimizing the cultural conditions affecting the growth and bioactive metabolite production by *Streptomyces gulbargensis* DAS 131 under submerged culture conditions in order to reduce the cost of fermentation process to improve the formation of antimicrobial compounds.

**Place and Duration of Study:** Department of Botany and Microbiology, January 2012 to May 2012.

**Methodology:** The impact of environmental parameters such as incubation period, pH, temperature and salt concentration and effect of various nutrients such as carbon and nitrogen sources and minerals on the antimicrobial metabolite production by *Streptomyces gulbargensis* DAS 131 was evaluated by employing agar well diffusion assay. Growth was measured in the form of dry mycelial weight.

**Results:** The optimum pH and temperature for bioactive metabolite production were 7 and 35°C respectively. Highest antimicrobial metabolite production was found when the strain was inoculated into the medium amended with glucose at the concentration of 2%, soya peptone at the rate of 1% and NaCl at the concentration of 5% and incubated for six days under shaking conditions. The metabolites showed good antimicrobial activity against Gram positive and Gram negative bacteria, as well as unicellular and multicellular fungi.

**Conclusion:** *S.gulbargensis* DAS 131 isolated from the semi-arid soils of Gulbarga, Northern Karnataka province, India exhibited broad spectrum antimicrobial activity. It was found that the antimicrobial metabolite production by the strain was positively influenced by carbohydrates, nitrogen sources and minerals.

13  
14 *Keywords: Optimization, Bioactive metabolites, Nutritional factors, Antimicrobial activity,*  
15 *Streptomyces gulbargensis* DAS 131  
16

17 **1. INTRODUCTION**  
18

19 The microbes are the source for many important drugs including antibiotics, antitumor  
20 compounds, Immunosuppressants, antiviral and antiparasitic agents. Over 10,000 of  
21 bioactive compounds have been produced by Actinomycetes which contribute to 45% of all

22 the bioactive secondary metabolites discovered [1]. Microbes dwelling in extreme habitats  
23 have been focused as an important source for novel compounds in recent years. The  
24 majority of studies with microbes from extreme environments were confined to bacteria and  
25 the actinomycetes from these habitats have been relatively less explored [2]. As highlighted  
26 in many reviews [3], natural products are the origin for most of the antibiotics in the market  
27 today. These products are an important source for both the existing and new drugs. Among  
28 these, actinomycetes are a biotechnologically priceless group of prokaryotes. Actinobacteria  
29 form a distinct line in the 16S rDNA tree and produce metabolites that have medical  
30 contribution from antibiotics to enzyme inhibitors. They are ubiquitously distributed in  
31 terrestrial, fresh water and extreme environments such as marine ecosystems and alkali  
32 soils [4]. They are considered to be the important group of microbes due to their ability to  
33 produce novel chemical compounds that are complex and commercially important (5). The  
34 solution to combat multidrug resistance of pathogens is to search for novel antimicrobial  
35 compounds so as to find a solution to overcome the global resistance to pathogenic bacteria.  
36

37 It is widely accepted that alkaliphilic actinomycetes are a valuable source for medicinal and  
38 industrial products [6]. Extensive exploration of actinomycetes having unique therapeutic  
39 properties continues to be an important area of research. *Streptomyces* species belonging to  
40 actinomycetes have been known as prolific producers of useful bioactive metabolites. These  
41 species are also recognized as industrially important organisms for their ability to synthesize  
42 different kinds of novel secondary metabolites, accounting for 70- 80% of all natural  
43 compounds produced by actinomycetes. *Streptomyces* are well documented as source for  
44 novel drug metabolites [7]. Some of the important compounds obtained from the  
45 alkaliphilic *Streptomyces* species include Pyrocoll [8], Chinikomycin and Lajollamycin,  
46 Mediomyocins A and B, Clethramycin [9], Bleomycin [10] and Caboxamycin [11] with anti-  
47 tumor, anti-parasitic and anti-microbial properties. Several studies were aimed at isolation of  
48 *Streptomyces* and screening them for new antibiotics. Novel actinomycetes documented and  
49 the products derived from poorly explored habitats stress the need to probe into new  
50 habitats [2].  
51

52 Media supplemented with carbon, nitrogen sources [12], sodium chloride [13] and mineral  
53 salts [14] and physico-chemical parameters like temperature, pH and incubation period also  
54 play a major role on growth and production of anti-microbial metabolites. The type, addition,  
55 removal and concentration of carbon, nitrogen, and phosphate together with trace elements  
56 are reported to influence the antibiotic biosynthesis by *Streptomyces* [15]. In order to achieve  
57 the highest level of metabolite production, the optimization of process parameters is very  
58 critical [16, 17]. Hence an effort was made to understand the impact of different carbon and  
59 nitrogen sources, temperature, pH and incubation period on growth and bioactive metabolite  
60 production by *Streptomyces gulbargensis* DAS131.  
61

## 62 2. MATERIALS AND METHODS

### 63 2.1. Isolation

64  
65 During the course of screening for industrially important microorganisms, an alkali-tolerant  
66 and thermo-tolerant actinomycete isolate identified as *Streptomyces gulbargensis* DAS 131  
67 was isolated from semi-arid soils of Gulbarga, Northern Karnataka province, India, by  
68 standard serial dilution technique using starch casein agar medium [18] and further  
69 maintained on Yeast extract malt extract dextrose (ISP-2) agar medium at 4 °C [19]. The 16S  
70 rRNA gene sequence of the strain has been deposited in the NCBI genbank with the  
71 accession number DQ317411 [20].  
72

73 **2.2. Selection of culture conditions for the optimum production of bioactive**  
74 **metabolites**

75 Antimicrobial metabolite production by the strain was optimized by using different  
76 parameters such as incubation period, pH, temperature, NaCl, carbon, nitrogen sources and  
77 minerals.

78  
79 **2.3. Effect of Incubation period**

80 The growth pattern and bioactive metabolite production by the strain was studied at regular  
81 intervals up to 10 days. One week old culture of *S. gulbargensis* DAS 131 was cultivated in  
82 ISP-2 broth (seed medium) comprising of yeast extract (0.4%), malt extract (1%), dextrose  
83 (0.4%), CaCO<sub>3</sub> (0.2%) with pH 7.2 at 37°C for 48 h. Seed culture at a rate of 10% was  
84 inoculated into the starch casein broth (production medium) consisting of soluble starch  
85 (1%), sodium caseinate (0.2%), K<sub>2</sub>HPO<sub>4</sub> (0.02%), MgSO<sub>4</sub>·7H<sub>2</sub>O (0.02%) FeSO<sub>4</sub>·7H<sub>2</sub>O  
86 (0.001%) with pH 7.2. The fermentation process was carried out for 10 days under agitation at  
87 150 rpm. At every 24 h interval, the flasks were harvested and the biomass was separated  
88 from the culture filtrate. Biomass was determined in terms of dry weight and antimicrobial  
89 metabolite production was determined in terms of their antimicrobial spectrum [21]. The  
90 crude bioactive compound produced in the fermentation medium by the isolate was  
91 extracted twice with equal volume of ethyl acetate (1:1) in a separating funnel at periodic  
92 intervals. The solvent layer was collected and evaporated in a rotary evaporator under  
93 vacuum. The crude residue thus obtained was dissolved in DMSO (dimethylsulfoxide) at a  
94 concentration of 1000 µg/ml and employed for antimicrobial activity against test  
95 microorganisms like *Streptococcus mutans* (MTCC 497), *Staphylococcus aureus* (MTCC  
96 3160), *Salmonella typhi* (ATCC 14028), *Pseudomonas aeruginosa* (ATCC 9027) and  
97 *Candida albicans* (ATCC 10231) by agar well diffusion method [22].  
98  
99

100 **2.4. Effect of pH and temperature**

101 To determine the influence of initial pH on growth and bioactive metabolite production, the  
102 strain was cultivated in the medium with different initial pH values ranging from 5 to 10 for six  
103 days. The strain was inoculated into production medium and grown at temperatures ranging  
104 from 20 to 50°C at pH 7 for six days to study the impact of temperature. The biomass and  
105 bioactive metabolite production were estimated and optimal pH and temperature achieved in  
106 this step was used for subsequent study.  
107

108 **2.5. Effect of NaCl concentration**

109 The impact of salinity on growth and bioactive metabolite production by *S. gulbargensis* DAS  
110 131 was recorded by cultivating the strain in the fermentation medium amended with different  
111 concentrations of NaCl (1-10%) at optimum pH and temperature for six days. The salt  
112 concentration in which the strain exhibits optimum levels of bioactive metabolites was fixed  
113 for further studies.  
114

115 **2.6. Effect of carbon and nitrogen sources**

116 To determine the effect of carbon sources on biomass and bioactive metabolite production,  
117 different carbon sources like galactose, lactose, fructose, sucrose, glucose, starch, mannitol,  
118 arabinose, raffinose and rhamnose each at a concentration of 1% were added separately  
119 into the production medium, maintaining all other conditions at optimum levels. The effect of  
120 varying concentrations of the best carbon source (0.5 - 5%) on bioactive metabolite  
121 production was examined. Similarly, the influence of various nitrogen sources on

122 antimicrobial metabolite production was evaluated by amending different nitrogen sources  
123 like soya peptone, arginine, asparagine, meat extract, yeast extract, tryptone, soya flour,  
124 casein, beef extract and glycine each at a concentration of 0.5% were individually  
125 supplemented into the production medium containing an optimum amount of the superior  
126 carbon source. The growth and production of bioactive metabolite was determined after six  
127 days of incubation at optimum pH, temperature and salt concentration. Further, the impact of  
128 varying concentrations of optimized nitrogen source (0.1-2%) was studied to standardize the  
129 maximum antimicrobial metabolite production.

130

## 131 **2.7. Impact of K<sub>2</sub>HPO<sub>4</sub>**

132 To study the impact of K<sub>2</sub>HPO<sub>4</sub> on growth and bioactive metabolite production, the strain  
133 was grown in the fermentation medium amended with different concentrations of K<sub>2</sub>HPO<sub>4</sub>  
134 (0.01 to 0.1%), maintaining all other conditions at optimum levels.

135

## 136 **2.8. Statistical analysis**

137 Results on cell growth and the production of bioactive metabolites by *S. gulbargensis* DAS  
138 131 exposed to different cultural conditions are statistically analyzed with two way analysis of  
139 variance (ANOVA).

140

## 141 **2.9. Bioassays**

142 The metabolites produced by the strain under optimized conditions were tested against  
143 bacteria and fungi by agar-well diffusion assay (22). The test microorganisms used to  
144 evaluate the production of bioactive metabolites were *Staphylococcus aureus*(MTCC 3160),  
145 *Streptococcus mutans* (MTCC 497), *Bacillus subtilis* (ATCC 6633), *Lactobacillus*  
146 *casei*(MTCC 1423), *Lactobacillus acidophilus* (MTCC 495), *Xanthomonas campestris*  
147 (MTCC 2286), *Bacillus megaterium* (NCIM 2187), *Escherichia coli* (ATCC 35218),  
148 *Enterococcus faecalis* (MTCC 439), *Pseudomonas aeruginosa*(ATCC 9027), *Salmonella*  
149 *typhi*(ATCC 14028), *Proteus vulgaris* (MTCC 7299), *Candida albicans* (ATCC 10231),  
150 *Aspergillus niger*(ATCC 1015), *Aspergillus flavus*(ATCC 9643), *Fusariumoxysporum*(MTCC  
151 3075) and *Penicilliumcitrinum*(MTCC 6489).

152

## 153 **RESULTS AND DISCUSSION**


154

### 155 **3.1. Effect of incubation period**

156

157 The growth pattern of *S. gulbargensis* DAS 131 was studied on starch casein broth.  
158 Exponential phase of the strain extended from lag phase after 24 h to 72 h. After that it  
159 exhibited stationary phase from 96 h to 144 h of incubation, then declined (Fig.1).The results  
160 revealed that the antimicrobial metabolite was early produced and reached maximum at the  
161 stationary phase. The cessation of growth in the stationary phase is most commonly caused  
162 by the exhaustion of the essential nutrients of the medium as well as accumulation of  
163 undesirable metabolites. The secondary metabolites obtained from six day old culture  
164 exhibited high antimicrobial activity against the test microorganisms. Thakur *et al.* [7] stated  
165 that the maximum incubation period required for optimum growth and antibiotic yield by the  
166 isolate *Streptomyces* sp. 201 was six days which was in complete accordance with the  
167 earlier report [23]. The incubation period for the production of bioactive metabolites seems to  
168 vary among *Streptomyces* strains. Metabolites elaborated from 5 day old culture of  
169 *Streptomyces* sp. KGG32 [24] and *S.ramulosus*-AZ-SH-29[25] showed good antimicrobial  
170 activity. Metabolites collected from 10-day old culture of *S.crystallinus* AZ-A151 producing  
171 Hygromycin-B exhibited good anti-microbial activity [26].

172



173  
174  
175

Fig.1. Growth pattern and anti-microbial activity of *S. gulbargensis* DAS 131.

176 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
177 found to be significant at 1%.

178

179

### 3.2. Effect of initial pH and incubation temperature

180

181

182

183


184

185

186

187

The environmental requirements and cultural conditions for growth and bioactive metabolite production by *S. gulbargensis* DAS 131 were studied. The antimicrobial metabolite production was found to be influenced by pH of the medium. The maximum biomass and bioactive metabolite production by the strain was obtained at pH 7 suggesting its inclusion in the neutrophilic actinomycetes group (Fig. 2). Medium maintained at pH 7.0 was reported to support enhanced anti-microbial metabolite production by *Streptomyces rochei* G 164 [27], *Streptomyces marinensis* [28], *Streptomyces albidoflavus* [21], *Streptomyces torulosus* KH-4 [29], *Streptomyces* spp. VITSVK9 [30] and *Streptomyces cheonanensis* VUK-A [31].



188

189

190

191

Fig. 2. Effect of pH on growth and bioactive metabolite yield of *S. gulbargensis* DAS 131


192

193

194

\*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and found to be significant at 1%.

195 The effect of temperature on growth and bioactive metabolite production of the strain was  
 196 recorded (Fig.3). There was an increase in the growth as well as bioactive metabolite  
 197 production with the increase of incubation temperature from 20°C to 35°C. However further  
 198 increase in temperature (above 35°C) resulted in the decline of growth and bioactive  
 199 metabolite production. In terms of its optimum temperature for growth, the organism  
 200 appeared to be mesophilic in nature. Atta *et al.* [26] reported that *Streptomyces crystallinus*,  
 201 AZ-A151 produced high levels of Hygromycin-B production at 35°C. Ushakiranmayi *et al.*  
 202 [33] stated that the optimum temperature capable of promoting antimicrobial metabolite  
 203 produced by *Pseudonocardia* sp. VUK-10 isolated from Nizampatnam mangrove ecosystem  
 204 was 35°C.  
 205  
 206




207  
 208  
 209  
 210 Fig.3. Effect of temperature on growth and bioactive metabolite yield of *S.gulbargensis* DAS  
 211

131

212 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
 213 found to be significant at 1%.  
 214

215 **3.3. Effect of NaCl**

216 Optimum salt requirement for bioactive metabolite production was examined in the  
 217 production medium supplemented with different salt concentrations ranging from 1-10%.  
 218 NaCl at the concentration of 5% was found to be optimum for maximum growth as well as  
 219 antimicrobial compound production by *S.gulbargensis* DAS 131 (Fig. 4). Further increase in  
 220 salt concentration reduced the antimicrobial agent biosynthesis. The requirement of NaCl for  
 221 the production of bioactive metabolites seems to be different among actinomycete strains.  
 222 Optimum NaCl concentration for maximum growth as well as antimicrobial metabolite  
 223 production was reported to be 2% for *Streptomyces tanashiensis* A2D [2], 1% for  
 224 *Streptomyces felleus* YJ1 [36] and 5% for *Streptomyces* VITSVK9 [30].  
 225  
 226



227  
228  
229

Fig. 4. Effect of NaCl on growth and bioactive metabolite yield of *S. gulbargensis* DAS 131.


230 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
231 found to be significant at 1%.

232

### 233 3.4. Effect of carbon and nitrogen sources

234

235 The effect of carbon sources on biomass and bioactive metabolite production by *S.*  
236 *gulbargensis* DAS 131 was evaluated. The production of biomass was high with lactose  
237 followed by sucrose and starch, while significant bioactive metabolite production was  
238 obtained by the strain in glucose amended media followed by galactose and fructose. El-  
239 Enshasy *et al.* [39] reported that glucose and sucrose in pure or in polymer forms were the  
240 best C-sources for erythromycin production. Antibiotic production from alkaliphilic  
241 *S.tanashiensis* strain A2D was high in medium containing glucose as carbon source [2].  
242 Similarly glucose was found to be the best carbon source for antibiotic production by  
243 *Streptomyces torulosus*KH-4 [29], *S. griseocarneus* [40] and *S. kanamyceticus* M27 [41].  
244




245  
246

247 Fig. 5. Effect of different carbon sources on growth and bioactive metabolite yield of *S.*  
248 *gulbargensis* DAS 131.

249 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
250 found to be significant at 1%.



251 As glucose emerged as the most preferred carbon source for bioactive metabolite production  
 252 by the strain, varying concentrations of glucose (0.5-5%) was tested to determine its optimal  
 253 concentration. It is noted that glucose at 3% and 2% concentrations showed optimal yields of  
 254 biomass and bioactive metabolites respectively (Fig.6).Medium containing 2% glucose  
 255 supported maximum levels of Natamycin production by *Streptomyces natalensis* and  
 256 *Thermomonospora* spp. [38, 42] while Atta *et al.* [25] reported that medium containing 2.5%  
 257 glucose supported antibiotic production by *Streptomyces ramulosus* AZ-SH-29.  
 258




259  
 260  
 261 Fig.6. Effect of different concentrations of glucose on growth and production of bioactive  
 262 metabolite by *S.gulbargensis* DAS 131.

263 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
 264 found to be significant at 1%.  
 265

266 Nitrogen sources are important for the production of bioactive metabolites by  
 267 microorganisms. Changes in the nature and concentration of nitrogen source seem to affect  
 268 antibiotic biosynthesis in different organisms. Different nitrogen sources were found to have  
 269 significant effect on growth and secondary metabolite production by *S. gulbargensis* DAS  
 270 131. Among the nitrogen sources tested amendment of soya peptone in the culture medium  
 271 enhanced the biomass and bioactive metabolite production by the strain (Fig. 7). Viana *et al.*  
 272 [43] recorded that soya bean flour increased the clavulanic acid production by *Streptomyces*  
 273 DAUFPE 3060. In contrast Thakur *et al.* [7] found that basal medium amended with  
 274 asparagine as nitrogen source was proved to be the best for 2-methylheptyl isonicotinate  
 275 production by *Streptomyces* sp.201.  
 276





277  
278

279 Fig.7. Effect of different nitrogen sources on growth and bioactive metabolite production by  
280 *S. gulgargensis* DAS 131.


281

282 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
283 found to be significant at 1%.

284

285 Influence of different concentrations of soya peptone on the production of bioactive  
286 metabolites is represented in Fig.8. It is noted that soya peptone at a concentration of 1.5%  
287 and 1% exhibited optimal production of biomass and bioactive metabolites respectively.  
288 Himabindu and Jetty [44] reported that soya bean meal at a concentration of 1% and 0.5%  
289 enhanced growth and gentamicin production by *Micromonospora echinospora*. Whereas Qin  
290 Song *et al.* [36] stated that soya bean meal at a concentration of 2% increased the bioactive  
291 metabolite production by *Streptomyces felleus* YJ1.

292



293  
294

295 Fig.8. Effect of different concentrations of soya peptone on growth and production of  
296 bioactive metabolite by *S. gulgargensis* DAS 131.


297 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
298 found to be significant at 1%.

299

### 300 3.5. Effect of $K_2HPO_4$

301 Effect of  $K_2HPO_4$  on biomass and bioactive metabolite production by the strain (Fig. 9) was  
302 studied. A slight enhancement in growth and antimicrobial activity was obtained in medium  
303 supplemented with 0.05% of  $K_2HPO_4$ . Ripa *et al.* [32] reported that among different minerals

304 tested,  $K_2HPO_4$  showed positive influence on antibiotic production by *Streptomyces* RUPA-  
 305 08PR. Narayana and Vijayalakshmi [21] also recorded that  $K_2HPO_4$  slightly enhanced the  
 306 production of biomass and bioactive metabolites of *Streptomyces albidoflavus*. Production of  
 307 gentamicin by *M.purpurea* and antibiotic tylosin by a *Streptomyces* sp. was inhibited by high  
 308 phosphate concentrations [45, 46].  
 309  
 310



311  
 312  
 313 Fig.9. Impact of  $K_2HPO_4$  on growth and bioactive metabolite production of *S. gulbargensis*  
 314 DAS 131

315 \*Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and  
 316 found to be significant at 1%.  
 317

### 318 3.6. Bioassays

319 The antimicrobial metabolite produced by the strain under optimized conditions was tested  
 320 against various test bacteria and fungi (Table.1& Fig.10).Among the bacteria tested,  
 321 *Xanthomonas campestris*(MTCC 2286)and *Bacillus megaterium* (NCIM 2187)were highly  
 322 sensitive to the metabolites produced by *S.gulbargensis* DAS 131 followed by *Streptococcus*  
 323 *mutans*(MTCC 497)and *Enterococcus faecalis*(MTCC 439).Among the fungi tested, *Candida*  
 324 *albicans* (ATCC 10231)was highly sensitive to the metabolites produced by the strain  
 325 followed by *Aspergillus niger*(ATCC 1015) and *Aspergillus flavus* (ATCC 9643). A significant  
 326 antimicrobial activity was reported on the opportunistic and pathogenic bacteria and fungi  
 327 tested.  
 328


329 Table1. Antimicrobial activity of *S. gulbargensis* DAS 131 against opportunistic and  
 330 pathogenic bacteria and fungi under optimized conditions.  
 331

<b>Antimicrobial Activity of Bioactive Metabolite Produced by <i>S. gulbargensis</i> DAS 131 under Optimized Conditions</b>	
<b>Bacteria</b>	
<b>Test Microorganisms</b>	<b>Zone of Inhibition(mm)</b>
<i>Staphylococcus aureus</i> (MTCC 3160)	31
<i>Streptococcus mutans</i> (MTCC 497)	33

<i>Bacillus subtilis</i> (ATCC 6633)	30
<i>Lactobacillus casei</i> (MTCC 1423)	32
<i>Lactobacillus acidophilus</i> (MTCC 495)	31
<i>Xanthomonas campestris</i> (MTCC 2286)	34
<i>Bacillus megaterium</i> (NCIM 2187)	33
<i>Escherichia coli</i> (ATCC 35218)	31
<i>Enterococcus faecalis</i> (MTCC 439)	33
<i>Pseudomonas aeruginosa</i> (ATCC 9027)	30
<i>Salmonella typhi</i> (ATCC 14028)	27
<i>Proteus vulgaris</i> (MTCC 7299)	28
<b>Fungi</b>	
<i>Candida albicans</i> (ATCC 10231)	32
<i>Aspergillus niger</i> (ATCC 1015)	27
<i>Aspergillus flavus</i> (ATCC 9643)	26
<i>Fusariumoxysporum</i> (MTCC 3075)	19
<i>Penicilliumcitrinum</i> (MTCC 6489)	20

332

333



334  
335

336 FIG. 10: Antimicrobial activity of *S.gulbargensis* DAS 131 against  
337 *A.Pseudomonasaeruginosa*(ATCC 9027)B. *Escherichia coli*(ATCC 35218)C.  
338 *Salmonellatyphi*(ATCC 14028)D. *Bacillus subtilis*(ATCC 6633)E.*Candida albicans*(ATCC  
339 10231).

340

#### 341 4. CONCLUSION

342 In the present study *S.gulbargensis* DAS 131exhibited high antimicrobial activity when  
343 cultured on production medium amended with glucose (2%),soya peptone (1%), NaCl (5%)  
344 and  $K_2HPO_4$  (0.05%)at pH 7 for six days of incubation at 35°C. Among the bacteria tested,  
345 *Xanthomonas campestris* and *Bacillus megaterium* were highly sensitive to the metabolites  
346 produced by the strain while *Candida albicans* exhibited high sensitivity followed by  
347 *Aspergillus niger*among fungi.This is the first report on the optimization of bioactive  
348 metabolites produced by *S.gulbargensis* DAS 131.  
349

350

#### 350 ACKNOWLEDGEMENTS:

351 Financial assistance from CSIR, New Delhi is gratefully acknowledged.

352

#### 352 COMPETING INTERESTS

353 Authors have declared that no competing interests exist.

354

#### 355 AUTHORS' CONTRIBUTIONS

356 UKM performed the experimental part, MVL& DA designed the study and SP performed  
357 literature search and statistical analysis. All authors read and approved the final manuscript.  
358

359 **REFERENCES**

360

361

[1]. Bérdy J. Bioactive microbial metabolites. JAntibiot. 2005; 58 (1): 1-26.

362

363

[2]. Singh LS, Mazumdar S, Bora TC. Optimization of process parameters for growth and bioactive metabolite production by a salt-tolerant and alkaliphilic actinomycete, *Streptomyces tanashiensis* strain A2D. Journal de Mycologie Medicale. 2009; 19 (4): 225-223.

364

365

366

367

368

[3]. Blunt JW, Copp BR, Munro MHJ, Northcote PT, Prinsep MR. Marine natural products. Natural Product Reports. 2010; 27 (2): 165-237.

369

370

371

[4]. Shuvankar B, Syed GD, Savita K. Biotechnological significance of actinobacterial research in India. Recent Research in Science and Technology.2012; 4(4): 31-39.

372

373

374

375

[5]. Hopwood DA. Therapeutic treasures from the deep. Nature Chemical Biology.2007; 3 (8): 457-458.

376

377

378

[6]. Mitsui S, Sakai M, Moriyama Y, Goto M, Furukawa K. Purification and some properties of keratinolytic enzyme from an alkaliphilic *Nocardopsis* spp. TOA-1. BiosciBiotechnolBiochem. 2002; 66 (1):164-167.

379

380

381

382

[7]. Thakur D, Bora TC, Bordoloi GN, Mazumdar S. Influence of nutrition and culturing conditions for optimum growth and antimicrobial metabolite production by *Streptomyces* spp.201. Journal de Mycologie Medicale.2009; 19 (3): 161-167.

383

384

385

386

[8]. Dietera A, Hamm A, Fiedler HP, Good fellow M, Muller WA, Brun RP. An antibiotic, antiparasitic and antitumor compound produced by a novel alkaliphilic *Streptomyces* strain. J Antibiot. 2003; 56 (7):639-646.

387

388

389

390

[9]. Cai P, Kong F, Fink P, Ruppen ME, Williamson RT, Keiko T. Polyene Antibiotics from *Streptomyces mediocidicus*. J Nat Prod.2007; 70 (2):215-219.

391

392

393

[10]. Chen C, Si S, He Q, Xu H, Lu M, Xie Y. Isolation and characterization of antibiotic NC0604, a new analogue of bleomycin. J Antibiot.2008; 61(12):747-751.

394

395

396

[11]. Hohmann C, Schneider K, Bruntner C, Irran E, Nicholson G, Bull AT. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain *Streptomyces* spp. NTK 937. J Antibiot. 2009; 62 (2):99-104.

397

398

399

400

[12]. Adinarayana K, Prabhakar T, Srinivasulu V, Rao AM, Jhansi LP. Optimization of process parameters for cephalosporin C production under solid state fermentation from *Acremoniumchrysogenum*. Process Biochem. 2001; 39 (2): 171-177.

401

402

403

404

405

[13]. Noaman NH, Fattah A, Khaleafa M, Zaky SH. Factors affecting antimicrobial activity of *Synechococcusleopoliensis*. Microbiol Res. 2004; 159 (4): 395-402.

406

- 407  
408 [14].Basak K, Majumdar SK. Mineral nutrition of *Streptomyceskanamyceticus* for Kanamycin  
409 formation. Antimicrob Agents Chemother. 1975; 8 (4):391-395.  
410
- 411 [15]. Loun'es A, Lebrihi A, Benslimance C, Lefebvre G, Germain P. Regulation of spiramycin  
412 synthesis in *Streptomyces ambofaciens*: effect of glucose and inorganic  
413 phosphate. J MicrobiolBiotechnol. 1996; 45 (1-2): 204-211.  
414
- 415 [16]. Moita C, Feio SS, Nunes L, Joa M, Curto M. Optimization of physical factors on the  
416 production of active metabolites by *Bacillus subtilis* 355 against wood surface  
417 contaminant fungi. IntBiodeteriorBiodegrad. 2005; 55 (4): 261-269.  
418
- 419 [17]. Krishnakumar S, Premkumar J, Alexis Rajan R, Ravikumar S. Optimization of potential  
420 antibiotic production by salt-tolerant actinomycetes *Streptomyces* spp. MSU29  
421 isolated from marine sponge. Int J Applied Bioengineering. 2011; 5(2): 12-17.  
422
- 423 [18]. Kuster K, Williams ST. Selection of media for isolation of *Streptomyces*. Nature. 1964;  
424 202(4935): 928-929.  
425
- 426 [19].Williams ST, Cross T. Isolation, Purification, Cultivation and Preservation of  
427 Actinomycetes. In Booth C, editor. Methods Microbiology. 4: 295-334, 1971.  
428
- 429 [20]. Dastager GS, Wen A, Dayanand BS, Mudgulkar KT, Shu PT, Xin, Xiao YZ.  
430 *Streptomyces gulbargensis* sp. nov, isolated from soil in Karnataka, India.  
431 Antonie van Leeuwenhoek. 2007; 91 (2): 99-104.  
432
- 433 [21]. Narayana KJP, Vijayalakshmi M. Optimization of antimicrobial metabolites production  
434 by *Streptomyces albidoflavus*. Research journal of pharmacology. 2008; 2 (1): 4-  
435 7.  
436
- 437 [22]. Cappuccino JG, Sherman N. Microbiology, Laboratory manual. Person education, INC,  
438 New Delhi; 2004.  
439
- 440 [23]. Yarbrough GG. Screening microbial metabolites for new drugs, theoretical and practical  
441 issues. J Antibiot. 1993; 46 (4):535-544.  
442
- 443 [24].Oskay M. Effects of some Environmental Conditions on Biomass and Antimicrobial  
444 Metabolite Production by *Streptomyces* spp., KGG32. Int J Agric Biol. 2011; 13  
445 (3): 317-324.  
446
- 447 [25].Atta HM, Bahobail AS, El-Sehrawi MH. Studies on Isolation, Classification and  
448 Phylogenetic characterization of antifungal substance produced by  
449 *Streptomyces albidoflavus*-143. New York Science Journal. 2011; 4 (3): 40-53.  
450
- 451 [26].Atta HM, Afifi MM, Elshanawany AA, Abdoul-raouf AU, El-Adly AM. Production of  
452 Hygromycin-B antibiotic from *Streptomyces crystallanius*. AZ-A151: II.  
453 Parameters controlling of antibiotic production. Academia Arena. 2012; 4 (3):  
454 37-52.  
455

- 456 [27].Chattopadhyay D, Sen SK. Optimization of cultural conditions for antifungal antibiotic  
457 accumulated by *Streptomycesrochei*G 164. Hindustan Antibiot Bull. 1997; 39  
458 (1): 64-71.  
459
- 460 [28] Adinarayana K, Ellaiah P, Srinivasulu B, Bhavani R, Adinarayana G. Response surface  
461 methodological approach to optimize the nutritional parameters for neomycin  
462 production by *Streptomyces marinensis* under solid state fermentation. Process  
463 Biochemistry. 2003; 38 (11):1565-1572.  
464
- 465 [29].Atta HM, Bayoumi R, El-Sehrawi M, Aboshady A, Al-Humiany A. Biotechnological  
466 application for producing some anti-microbial agents by actinomycetes isolates  
467 from Al-Khurmah Governorate. European Journal of Applied Sciences. 2010; 2  
468 (3): 98-107.  
469
- 470 [30]. Saurav K, Kannabiran, K. Diversity and Optimization of process parameters for the  
471 growth of *Streptomyces VITSVK 9* sp. Isolation from Bay of Bengal, India.  
472 Journal of Natural and Environment sciences 2010; 1(2): 56-65.  
473
- 474 [31].Ushakiranmayi M, Sudhakar P, Krishna N, Vijayalakshmi M. Influence of cultural  
475 conditions for improved production of bioactive metabolites by *Streptomyces*  
476 *cheonanensis* VUK-A isolated from Coringa Mangrove Ecosystem. Current  
477 Trends in Biotechnology and Pharmacy. 2012; 6 (1): 99-111.  
478
- 479 [32].Ripa FA, Nikkon F, Zaman S, Khondkar P. Optimal conditions for antimicrobial  
480 metabolites production from a new *Streptomyces* spp.Rupa-08 isolated from  
481 Bangladesh Soil. Mycobiology. 2009; 37 (3): 211-214.  
482
- 483 [33].MangamuriUshaKiranmayi, PodaSudhakar, Kammasrinivasulu, Muvva Vijayalakshmi.  
484 Optimization of culturing conditions for improved production of bioactive  
485 metabolites by *Pseudonocardia* spp. VUK-10. Mycobiology. 2011; 39 (3): 174-  
486 181.  
487
- 488 [34]. Kunnari T, Tuikkanen J, Hautala A, Hakala J, Ylihonko, K, Mantsala, P. Isolation and  
489 characterization of 8- demethoxysteffimycins in *Streptomyces steffisburgensis*  
490 by the nogalamycin biosynthesis genes. J Antibiot. 1997; 50 (6):496-501.  
491
- 492 [35].Saha MR, Rifa FA, Islam MZ, Khondkar, P. Optimization of conditions and in vitro  
493 antibacterial activity of secondary metabolite isolated from *Streptomyces* spp.  
494 MNK 7. Journal of Applied Science Research. 2010; 6(5):453-459.  
495
- 496 [36].Qin Song, Yun Huang, Hui Yang. Optimization of fermentation conditions for antibiotic  
497 production by actinomycetes YJ1 strain against *Sclerotiniasclerotiorum*. J Agri  
498 Sci. 2012; 4 (7): 95-102.  
499
- 500 [37].Casida LE. Fermentation media, In: Casida, L.E. editor. Industrial Microbiology, John  
501 Wiley and Sons, Inc, New York, USA; pp: 117-135, 1987.  
502
- 503 [38].Farid MA, El-Enshasy HA, Ei-Diwany AI, El-sayed EA. Optimization of the cultivation  
504 medium for Natamycin production by *Streptomyces netalensis*. J Basic  
505 Microbiol. 2000; 40 (3):157-166.



- 506 [39].El-Enshasy HA, Mohamed NA, Farid MA, El-Diwany AI. Improvement of erythromycin  
507 production by *Saccharopolysporaerythrea* in molasses based medium through  
508 cultivation medium optimization. *Bioresour Technol.* 2008; 99(10): 4263-4268.  
509
- 510 [40].Cruz R, Arias ME, Solveri J. Nutritional requirements for the production of phyla  
511 zoloisoquinolinone antibiotic by *Streptomycesgriseocarneus* NCIMB 40447.  
512 *ApplMicrobiolBiotechnol.* 1999; 53(1):115-119.  
513
- 514 [41].Pandey A, Shukla A, Majumdar SK. Utilization of carbon and nitrogen sources by  
515 *Streptomyces kanamyceticus* M 27 for the production of an antibacterial  
516 antibiotic. *Afr J Biotechnol.* 2005; 4(9): 909-910.  
517
- 518 [42].Gupte M, Kulkarni, P. A study of anti-fungal antibiotic production by *Thermomonospora*  
519 spp. MTCC 3340 using full factorial design. *J Chem Tech Biotechnol.*2003;  
520 78(6): 605-610.  
521
- 522 [43]. Viana DA, Carneiro-Cunha MN, Araujo JM, Barros-Neto B, Lima-Filho JL, Converti A *et*  
523 *al.* Screening of variables influencing the Clavulanic Acid Production by  
524 *Streptomyces* DAUFPE 3060 strain. *ApplBiochemBiotechnol.* 2010; 160(6):  
525 1797-1807.  
526
- 527 [44].Himabindu M, Annapurna J. Optimization of nutritional requirements for gentamicin  
528 production by *Micromonospora echinospora*. *Indian J Experimental Biol.* 2006;  
529 44: 842-848.  
530
- 531 [45].Wu JY, Jenn-Wen H, Sin-Der SH, Wei-Chenand L, Yungehuan L. Optimization of  
532 cultivation conditions for fungi chromin production from *Streptomyces padanus*  
533 PMS-702. *J Chin instChem Eng.* 2008; 39 (6):67-73.  
534
- 535 [46]. Majumdar MK, Majumdar SK. Effect of minerals on neomycin production by  
536 *Streptomyces fradiae*. *ApplMicrobiol.* 1965; 13 (2): 190-193.  
537  
538  
539  
540  
541  
542